Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection
Jonathan Zalevsky(Nektar Therapeutics (United States)), David E. Szymkowski(Xencor (United States)), Thomas Sécher(Université de Tours), Paul M. Steed(Serdang Hospital), François Erard(Centre National de la Recherche Scientifique), Araz Eivazi(Xencor (United States)), Sergei A. Ezhevsky(Xencor (United States)), James Kung(Xencor (United States)), Duc-Hanh T. Nguyen(Xencor (United States)), Laure Janot(Centre National de la Recherche Scientifique), Stephen K. Doberstein(Xencor (United States)), Christopher J. O’Brien(Children’s Health Queensland Hospital and Health Service), Bernhard Ryffel(Immunologie et Neurogénétique Expérimentales et Moléculaires)
Cited by 161
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403